Field report NW-38 / L6 · sheet /expansion

Expansion & MarketsFiled from the territory

Sellas Stock Explodes 233% as Leukemia Vaccine Cuts Death Risk 41%

Sellas Life Sciences jumped as much as 233% after its GPS leukemia vaccine cut death risk 41% in a Phase 3 trial, with median survival reaching 24.0 months versus 14.7 on standard care.

Grid
NW-38 / L6
Surveyed
November 20, 2026
Reading
3 min read
Correspondent
Priya Raman
Sellas Life Sciences stock soars as much as 233% after cancer vaccine cut death risk in trial
Fig. NW-38 / L6Sellas Life Sciences stock soars as much as 233% after cancer vaccine cut death risk in trial — geralt / pixabay

Field notes

  1. Sellas stock rose as much as 233% on Tuesday after positive Phase 3 topline results
  2. GPS vaccine lowered mortality risk 41%; median survival 24.0 vs 14.7 months, hazard ratio 0.59 (p=0.035)
  3. REGAL trial randomized 126 AML patients in second or later remission, all ineligible for stem cell transplant
  4. Biologics License Application planned for the first half of 2027
  5. GPS is a four-peptide vaccine targeting WT1, licensed from Memorial Sloan Kettering Cancer Center

Sellas Life Sciences stock soared as much as 233% on Tuesday after its leukemia vaccine cut the risk of death by 41% in a Phase 3 trial, hitting the study's primary endpoint of overall survival.

The vaccine, galinpepimut-S or GPS, extended median overall survival to 24.0 months in patients with acute myeloid leukemia (AML), compared with 14.7 months for those receiving the best available treatment, the company said. The hazard ratio (a measure of relative risk of an event, here death, between groups) came in at 0.59, with a p-value of 0.035 — statistically significant by conventional thresholds.

The stock reaction was the sharpest biotech move of the day's session, and it rests on a single number: the 41% mortality reduction.

What did the REGAL trial actually test?

The Phase 3 REGAL trial randomized 126 patients 1:1 to GPS monotherapy or to an investigator's choice of treatment. The control options were observation, a hypomethylating agent (a drug that reactivates silenced genes), venetoclax, low-dose cytarabine, or a combination of these.

All patients were in second or later remission. None could undergo an allogeneic stem cell transplant (a procedure replacing a patient's blood-forming cells with a donor's), because they were ineligible or unable to tolerate it.

That's the key clinical context. These are patients with limited options after remission, where maintenance therapy to keep the disease at bay is scarce.

The trial was open-label, meaning both doctors and patients knew which treatment was being given — a design limitation that regulators weigh when reviewing efficacy claims.

How safe was the vaccine?

GPS was generally well tolerated, with no new safety signals, Sellas said. Treatment-related adverse events were mostly mild to moderate, and the most common side effect was reactions at the injection site.

What happens next?

CEO Angelos Stergiou signaled the regulatory push is already underway. "We look forward to engaging with the FDA to discuss the results and the regulatory path forward, with the goal of making this therapy available to patients as rapidly as possible," he said in a statement.

Sellas plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy. The company is preparing a Biologics License Application (the FDA's approval pathway for biologic drugs) for GPS, targeting submission in the first half of 2027.

Secondary endpoint analysis is under way. Sellas said it will present the full results at a medical conference and submit them for peer-reviewed publication.

Why did the results arrive late?

The primary analysis was triggered by a pre-specified count of 80 deaths. Those deaths did not accumulate until late October, so the trial needed more time than expected to reach that threshold, according to Fierce Biotech.

A slower death count is, bluntly, not the worst problem a survival trial can have. It signals patients were living longer than the statistical design assumed.

What is GPS?

GPS is an off-the-shelf vaccine made of four peptides (short protein fragments) derived from WT1, a protein expressed in acute myeloid leukemia and other cancers. Sellas licensed the vaccine from Memorial Sloan Kettering Cancer Center.

The company is testing it as a maintenance therapy — treatment given after remission to prolong it — rather than as a front-line attack on the disease. The mechanism: train the immune system to recognize and kill cells displaying the WT1 protein, the marker that distinguishes residual leukemia from healthy tissue.

For AML patients who can't get a transplant, a 9.3-month median survival gain from a well-tolerated injection changes the standard of care conversation. Now the clock runs toward the FDA meeting, and then the 2027 filing.

via qz.com (Source)

Share this article:

More from Priya Raman

Priya Raman

Show full bio

Senior reporter covering technology and product news in corporate strategy and chief-executive leadership at CEO Frontier.

496 articles

Filed under

Adjacent sheets

« Previous articleNext article »

End of sheetNW-38 / L6 · November 20, 2026